According to Piper Jaffray, Watson Pharmaceuticals WPI, PT and rating are reiterated.
Piper Jaffray has reiterated a PT of $78 and a rating of Overweight. EPS estimates are currently set at $4.44 for FY11 and $6.09 for FY12, with estimates nearing $7 for FY13.
Watson closed yesterday at $68.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in